Drugs / NIVOCASAN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00874796 | May 2009 → Apr 2010 | chronic hepatitis C virus infection | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT00740610 | Aug 2008 → Aug 2009 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00725803 | Apr → Oct 2008 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIVOCASAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105721 ↗ |
| Known as | GS-9450 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00725803 ↗ |
| Known as | LB-84451 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105721 ↗ |
| Action | Inhibit | “GS-9450, a Caspase Inhibitor” NCT00725803 ↗3“Caspase-1 inhibitor” CHEMBL2105721 ↗ “Caspase-8 inhibitor” CHEMBL2105721 ↗ “Caspase-9 inhibitor” CHEMBL2105721 ↗ |
| Modality | Small molecule | — CHEMBL2105721 ↗ |
| Route | Oral | “GS-9450 capsules administered orally once daily” NCT00725803 ↗ |
| Target | CASP1 | “Caspase-1 inhibitor” CHEMBL2105721 ↗ |
| Target | CASP8 | “Caspase-8 inhibitor” CHEMBL2105721 ↗ |
| Target | CASP9 | “Caspase-9 inhibitor” CHEMBL2105721 ↗ |